Anzeige
Meldung des Tages: US-Goldprojekt vor dem Durchbruch: Warum Investoren jetzt aufmerksam werden

Citius Pharmaceuticals News

Aktie
WKN:  A40MD0 ISIN:  US17322U3068 US-Symbol:  CTXR Branche:  Pharmazeutika Land:  USA
0,805 $
-0,045 $
-5,29%
0,6883 € 10.04.26
Depot/Watchlist
Marktkapitalisierung *
5,52 Mio. €
Streubesitz
76,16%
KGV
-
Index-Zuordnung
-

Citius Pharmaceuticals News

22.08.25 - PR Newswire
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch PR Newswire
12.08.25 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
17.07.25 - PR Newswire
Citius Oncology Announces Closing of $9.0 Million Public Offering
Citius Oncology Announces Closing of $9.0 Million Public Offering PR Newswire
16.07.25 - PR Newswire
Citius Oncology Announces Pricing of $9.0 Million Public Offering
Citius Oncology Announces Pricing of $9.0 Million Public Offering PR Newswire
15.07.25 - PR Newswire
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora PR Newswire
08.07.25 - PR Newswire
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire
17.06.25 - PR Newswire
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
12.06.25 - PR Newswire
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
10.06.25 - PR Newswire
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
09.06.25 - PR Newswire
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health PR Newswire
14.05.25 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
05.05.25 - PR Newswire
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
07.04.26 -6,91%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »